Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Oblique Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oblique Therapeutics AB has Identified a Potentially Important Epitope for Generation of SARS-CoV-2 antibodies","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"SWEDEN","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery"},{"orgOrder":0,"company":"Oblique Therapeutics","sponsor":"Vinnova","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"Oblique Therapeutics Together with Collaborators at Sahlgrenska University Hospital and Karolinska Institutet Granted 5MSEK by Vinnova","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery"},{"orgOrder":0,"company":"Oblique Therapeutics","sponsor":"Targovax","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oblique Therapeutics and Targovax Enter Collaboration to Target Mutant Ras Cancers by Combining Their Oncos and Abiprot\u2122 Platforms","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Oblique Therapeutics

    Menu

    Oblique Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Oblique Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Oblique Therapeutics Together with Collaborators at Sahlgrenska University Hospital and Karolinska Institutet Granted 5MSEK by Vinnova

              Details:

              AbiprotTM can identify high-affinity antibody binding sites in any given protein with single amino acid resolution while the protein resides in its native environment.

              Lead Product(s): αSARS-CoV-2 antibodies

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Large molecule

              Partner/Sponsor/Collaborator: Vinnova

              Deal Size: $0.5 million Upfront Cash: Undisclosed

              Deal Type: Funding October 08, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Oblique Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Oblique Therapeutics and Targovax Enter Collaboration to Target Mutant Ras Cancers by Combining Their Oncos and Abiprot™ Platforms

              Details:

              Under the agreement the parties will jointly explore the technical feasibility and in vitro and in vivo functionality and anti-cancer activity of the ONCOSAbiprotTM combination, initially focusing on mutant RAS as the target.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Targovax

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration June 29, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Oblique Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Oblique Therapeutics AB has Identified a Potentially Important Epitope for Generation of SARS-CoV-2 antibodies

              Details:

              Using the AbiprotTM antibody discovery platform, a team of researchers has identified a potentially important epitope in SARS-CoV-2 that may facilitate generation of neutralizing antibodies to treat Covid-19 patients.

              Lead Product(s): Undisclosed

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 11, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY